



**FOR IMMEDIATE RELEASE**

**Contact:**

Bill Edelman  
CEO, TyRx Pharma, Inc.  
Office: 732-246-8676  
Direct: 732-964-1101  
Cell: 617-759-5451  
[william@tyrxpharma.com](mailto:william@tyrxpharma.com)

**TyRx Pharma, Inc. Announces Presentation of the Results of an In-Vivo Efficacy Study Regarding PIVIT™ CRM at the Heart Rhythm Society Meeting on May 11, 2007 in Denver, CO**

*PIVIT™ CRM is designed to reduce bacterial colonization of the mesh pouch and pulse generator during implantation*

**Monmouth Junction, NJ, (March 19 2007)** -- TyRx Pharma, Inc. announced today acceptance for presentation during the Heart Rhythm 2007 Society meeting, (May 9-12, 2007, Denver, CO) the paper entitled, "Prevention of Experimental Pulse Generator Pocket Infection by an Encapsulating Antibacterial-Coated Mesh". Victor Parsonnet, M.D., Director of the Pacemaker and Defibrillator Center in the Department of Surgery at Newark Beth Israel Medical Center (Newark, NJ), Principal Investigator, will present the paper. Dr. Parsonnet was a co-founder of the North American Society of Pacing and Electrophysiology (NASPE) in 1978. Dr. Parsonnet has written more than 700 publications, book chapters and text books, and has made numerous presentations in the fields of cardiac pacing and vascular and cardiac surgery. TyRx Pharma sponsored the study.

On October 16<sup>th</sup> TyRx Pharma, Inc., filed a Premarket Application for PIVIT™ CRM, an innovative mesh pouch coated with TyRx's proprietary bioresorbable polymer. These polymers contain the antimicrobial agents, rifampin and minocycline, and are designed to enclose a pacemaker or ICD pulse generator when implanted in the body. PIVIT™ CRM acts to provide protection from microbial colonization of the pulse generator during surgical implantation. According to a recent study presented during the Heart Rhythm Society 2006 Scientific Sessions (Boston) the University of Pittsburgh Medical Center noted that the 2003 national incident of infection for pacemakers was estimated to be 5.82% and for ICDs 3.71%. Recent market research indicates that more than 500,000 pulse generators are implanted each year.

"We are excited to be working with renowned individuals such as Dr. Parsonnet," said Bill Edelman, CEO of TyRx Pharma, "His study results help to validate the performance of our PIVIT™ CRM concept."

On January 28<sup>th</sup>, TyRx announced a strategic alliance with C. R. Bard for the licensing of certain TyRx technologies and proprietary know-how and co-development with a Bard subsidiary utilizing TyRx technology and manufacturing know-how with certain products of a Bard subsidiary.

This notice follows TyRx's February 26<sup>th</sup> announcement of the signing of a Manufacturing supply agreement with JFC and the January 28<sup>th</sup>, TyRx announcement of a strategic alliance with C. R. Bard for the licensing of certain TyRx technologies and proprietary know-how and co-development with a Bard subsidiary utilizing TyRx technology and manufacturing know-how with certain products of a Bard subsidiary.

On December 6<sup>th</sup>, TyRx was awarded ISO 9001:2000 and ISO 13485:2003 certification in addition to being certified as compliant with the Canadian Medical Devices Directives (CMDCAS), signifying compliance with internationally recognized standards in design, development and manufacturing of medical products.

### **About TyRx Pharma, Inc.**

TyRx Pharma, Inc., an ISO 9001:2000 and ISO 13485:2003 certified medical device manufacturer, commercializes combination medical products utilizing novel biomaterials technology licensed exclusively from Rutgers, The State University of New Jersey. Additionally, TyRx has exclusively licensed from Baylor College of Medicine and The University of Texas M. D. Anderson Cancer Center product patents and associated technologies to address the problem of postsurgical nosocomial infection. TyRx is deploying its capabilities across a broad range of combination products. The combination products sector (products incorporating both a drug & a device component) is expected to be the highest growth segment of the medical products industry and TyRx is positioned to be an innovative applications leader in the space. For more information, please visit [www.tyrxpharma.com](http://www.tyrxpharma.com).

### **About Newark Beth Israel Medical Center**

The Saint Barnabas Heart Center at Newark Beth Israel Medical Center provides a full range of advanced cardiac care to patients in the State of New Jersey and beyond. Full range of services include CT and MR cardiac imaging, innovative interventional techniques for acquired and congenital cardiovascular disease and minimally invasive cardiothoracic surgery that utilizes robotics for advanced techniques which lead to quicker patient recovery. It serves as the home of the largest Heart Failure and Transplant service in the state, providing innovative treatments for those suffering from advanced heart disease. The Saint Barnabas Heart Center at Newark Beth Israel Medical Center has performed over 400 cardiac transplants.